Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 202

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 15
Chunk 202
---
Offer Letter between the Registrant and Carole Ho, M.D., dated November 10, 2017.S-1333-22152210.811/13/201710.9Lease Agreement between the Registrant and HCP Oyster Point III LLC, dated September 24, 2015.S-1333-22152210.911/13/201710.10ÜExclusive License Agreement between the Registrant and Genentech, Inc., dated June 17, 2016.S-1333-22152210.1011/13/201710.11ÜLicense and Collaboration Agreement between the Registrant, F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H. and F-star Biotechnology Limited, dated August 24, 2016.S-1333-22152210.1111/13/201710.12ÜDevelopment and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017.S-1333-22152210.1211/13/201710.12.1#Amendment No. 2 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated January 18, 2018.10-K001-3831110.12.13/19/201810.12.2#Amendment No. 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated July 2, 2018.10-Q001-3831110.111/8/201810.12.3#Amendment No. 4 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated August 30, 2018.10-Q001-3831110.211/8/201810.12.4#Amendment No. 5 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated August 6, 2019.10-K001-3831110.12.42/26/2021

176

Table of Contents

10.12.5#Amendment No. 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 11, 2020.10-K001-3831110.12.52/26/202110.12.6#Amendment No. 6 to Development and Manufacturing Services Agreement between the Registrant